Search and Browse
Download
Enter Data
|
Assay Method Information |
|
| | Antiviral Activity |
| Description: | The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) cell line, a Huh7 human hepatoma cell line harboring an HCV replicon with a stable luciferase (Luc) reporter and three cell culture-adaptive mutations (Pietschmann, et al (2002) J. Virol. 76:4008-4021). The HCV replicon antiviral evaluation assay examined the effects of compounds at ten three-fold dilutions. Sub-confluent cultures of the ET line were plated out into 96-well plates that were dedicated for the analysis of cell viability (cytotoxicity) or antiviral activity and the next day drugs were added to the appropriate wells. Cells were processed 72 hr later when the cells are still sub-confluent. EC50 (concentrations inhibiting the HCV RNA replicon by 50%), CC50 (concentration decreasing cell viability by 50%) and SI (selective index: CC50/EC50) values were determined. HCV RNA replicon levels were assessed using the Bright-Glo Luciferase Assay System (Promega) to measure replicon-derived Luc activity. The CellTiter-Glo Luminescent Cell Viability Assay (Promega) was used to estimate cell viability. |
| Affinity data for this assay | |
|---|---|
| If you find an error in this entry please send us an E-mail | |
|
Home |
| |
Search |
| |
Deposit |
| |
SiteMap |
| |
About us |
| |
Email us |
| |
Info |
|
©2000 BindingDB. All rights reserved. |
|||||||||||||